Levena Biopharma Supplies GMP Linker-Toxin for Alteogen’s Her-2 ADC Program
November 30, 2017
Suzhou and Daejeon, November 30, 2017-- Levena Biopharma Co. Ltd., today announced a supply agreement with Alteogen, a public traded biotechnology company based in South Korea, to support the development of its leading antibody drug conjugate (ADC) product ALT-P7.
In August 2017, Alteogen announced its plan to start phase I clinical trial of ALT-P7, an ADC product utilizing Alteogen’s proprietary NextMabTM ADC technology, in patients with HER-2 positive breast cancer. Under this agreement, Levena Biopharma will provide GMP grade of linker-toxin for Alteogen’s clinical program. Levena Biopharma completed its GMP facility in 2017 and this is its first GMP supply agreement with a Korean partner. Earlier in 2017, Levena has supported partners in China and US for their linker-toxin GMP production.
About Alteogen Inc
Alteogen Inc. is a biopharmaceutical company devoted to develop the next generation long-acting biobetters which have properties of the increased in-vivo half life. ALTEOGEN is also developing monoclonal antibody biobetter with ALTEOGEN’s proprietary ADC (Antibody Drug Conjugate) technology and monoclonal antibody biosimilars with blockbuster market potential.
Based on excellent and experienced R&D professionals and our own original biotechnologies, ALTEOGEN is focusing on developing and marketing biobetters and biosimilars by partnership with global pharmaceutical companies.
About Levena Biopharma, Co., Ltd.
Levena Biopharma Co., Ltd., established in 2013, is a biotechnology company dedicated to enable novel antibody-drug conjugate (ADC) therapeutic development. The company offers partners site-specific conjugation technology (K-LOCK and C-LOCK) and novel proprietary linker toxin. Levena Biopharma currently operates in its research and manufacturing facilities in Suzhou, Nanjing and San Diego with capabilities from ADC discovery research, process/analytical development to GMP production of linker-toxin and ADC conjugate.
Openning of cGMP Facility in Suzhou, China
SAN DIEGO, May 2, 2017 /PRNewswire/ -- LevenaBiopharma (Levena), is a subsidiary of Sorrento Therapeutics, Inc. (NASDAQ: SRNE; "Sorrento"). Levana has three sites locations in San Diego, Suzhou, and Nanjing China. It announced today a recently completed construction project in Suzhou has finished the first phase of the new cGMP production facility with the release of a cGMP API. The second phase of this construction project will add an additional 24.5 K sq ft is to be completed in Q4 2017. This new state of art facility will provide the much needed expertise and resources for our domestic and international partners. Management expect to realize significant revenues utilizing the capacities and capabilities as a CRO/CMO in the development and commercial productions of Antibody Drug Conjugates by 2020.